When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients?

Tumori

Volumn 93, Issue 5, 2007, Pages 491-492

  Beda, Manuela ^a   Basso, Umberto ^a   Ghiotto, Cristina ^a   Monfardini, Silvio ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Brain metastasis; Breast cancer; Duration of treatment; HER2; Trastuzumab

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; PACLITAXEL; TRASTUZUMAB;

ADULT; ANAMNESIS; ARTICLE; BRAIN DISEASE; BRAIN METASTASIS; BREAST CANCER; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HUMAN; LIVER METASTASIS; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; PROTEIN EXPRESSION; RELAPSE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 36749039659     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160709300514     Document Type: Article

References (9)

1. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte PF, Green M, Ward C, Mayne K, Extra JM: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol, 23: 4247-4250, 2005
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344: 783-792, 2001.
3. Pusztai L, Esteva FJ: Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. Cancer Invest, 24: 187-191, 2006.
4. Tomao F, Miele E, Spinelli GP, Russillo M, La Ferla G, Tomao S: Trastuzumab in metastatic breast cancer. Eur J Gynaecol Oncol, 27: 247-249, 2006.
5. Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G, Howell A, Wardley AM: Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer, 91: 639-643, 2004.
6. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer, 97: 2972-2977, 2003.
7. Duchnowska R, Szczylik C: Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev, 31: 312-318, 2005.
8. Puente Vazquez J, Lopez-Tarruella Cobo S, Garcia-Saenz JA, Casado Herraez A, Moreno Anton F, Sampedrp Gimeno T, Bueno Muino C, Grande Pulido E, Martin Jimenez M, Diaz-Rubio E: Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies. Clin Transi Oncol, 8: 50-53, 2006.
9. Kirsch DG, Loeffler JS: Brain metastases in patients with breast cancer: new horizons. Clin Breast Cancer, 6: 115-124, 2005.